PT - JOURNAL ARTICLE AU - Ania Zylbersztejn AU - Ofran Almossawi AU - Nikesh Gudka AU - Daniel Tompsett AU - Bianca De Stavola AU - Joseph F Standing AU - Rosalind Smyth AU - Pia Hardelid TI - Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals AID - 10.1101/2021.04.15.21255460 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.15.21255460 4099 - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255460.short 4100 - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255460.full AB - Objectives Palivizumab is a monoclonal antibody which can prevent infection with respiratory syncytial virus (RSV). Due to its high cost, it is recommended for high-risk infants only. We aimed to determine the proportion of infants eligible for palivizumab treatment in England who receive at least one dose.Methods We used the Hospital Treatment Insights database containing hospital admission records linked to hospital pharmacy dispensing data for 43/153 hospitals in England. Infants born between 2010 and 2016 were considered eligible for palivizumab if their medical records indicated chronic lung disease (CLD), congenital heart disease (CHD), or severe immunodeficiency (SCID), and they met additional criteria based on gestational age at birth and age at start of the RSV season (beginning of October). We calculated the proportion of infants who received at least one dose of palivizumab in their first RSV season, and modelled the odds of treatment according to multiple child characteristics using logistic regression models.Results We identified 3,712 eligible children, of whom 2,479 (67%) had complete information on all risk factors. Palivizumab was prescribed to 832 of eligible children (34%). Being born at <30 weeks’ gestation, aged <6 months at the start of RSV season, and having two or more of CLD, CHD or SCID were associated with higher odds of treatment.Conclusion In England, palivizumab is not prescribed to the majority of children who are eligible to receive it. Doctors managing these infants might be unfamiliar with the eligibility criteria or are constrained by other considerations, such as cost.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by a Wellcome Trust Seed Award In Science, grant reference number 207673/Z/17/Z. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Research at UCL Great Ormond Street Institute of Child Health is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study protocol was approved by Independent Scientific and Ethical Advisory Committee (ISEAC), protocol number HTI_17ISEAC_001.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe HTI is maintained by IQVIA (https://www.iqvia.com/). Copyright (c) 2019, re-used with the permission of The Health & Social Care Information Centre. All rights reserved. Copyright (c) 2021, re-used with the permission of IQVIA. All rights reserved. Authors do not have permission to share patient-level HTI data. Qualified researchers can request access to the data from IQVIA (contact Tanith Hjelmbjerg, tanith.hjelmbjerg@iqvia.com). All study protocols are subject to review by an Independent Scientific and Ethical Advisory Committee (ISEAC).